

1 Non-Adherence Tree Analysis (NATA) - an adherence improvement framework: a COVID-19 case  
2 study

3

4

5 Ernest Edifor<sup>1\*</sup>, Regina Brown<sup>2</sup>, Paul Smith<sup>3</sup>, Rick Kossik<sup>4</sup>

6

7 <sup>1</sup>Operations, Technology, Events and Hospitality Management, Manchester Metropolitan University,  
8 Manchester, Lancashire, UK

9 <sup>2</sup>Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA

10 <sup>3</sup>Marketing, Retail and Tourism, Manchester Metropolitan University, Manchester, Lancashire, UK

11 <sup>4</sup>Research and Development, GoldSim Technology Group LLC, Seattle, Washington, USA

12

13 \*Corresponding author

14 Email: e.edifor@mmu.ac.uk (EE)

15

16

17

## 18 **Abstract**

19 Poor adherence to medication is a global phenomenon that has received a significant amount of  
20 research attention yet remains largely unsolved. Medication non-adherence can blur drug efficacy  
21 results in clinical trials, lead to substantial financial losses, increase the risk of relapse and  
22 hospitalisation, or lead to death. The most common methods measuring adherence are post-treatment  
23 measures; that is, adherence is usually measured after the treatment has begun. What the authors are  
24 proposing in this multidisciplinary study is a technique for analysing the factors that can cause non-  
25 adherence before or during medication treatment.

26 Fault Tree Analysis (FTA), allows system analysts to determine how combinations of simple faults of  
27 a system can propagate to cause a total system failure. Monte Carlo simulation is a mathematical  
28 algorithm that depends heavily on repeated random sampling to predict the behaviour of a system. In  
29 this study, the authors propose the use of Non-Adherence Tree Analysis (NATA), based on the FTA  
30 and Monte Carlo simulation techniques, to improve adherence. Firstly, the non-adherence factors of a  
31 medication treatment lifecycle are translated into what is referred to as a Non-Adherence Tree (NAT).  
32 Secondly, the NAT is coded into a format that is translated into the GoldSim software for performing  
33 dynamic system modelling and analysis using Monte Carlo. Finally, the GoldSim model is simulated  
34 and analysed to predict the behaviour of the NAT.

35 This study produces a framework for improving adherence by analysing social and non-social  
36 adherence barriers. The results reveal that the biggest factor that could contribute to non-adherence to  
37 a COVID-19 treatment is a therapy-related factor (the side effects of the medication). This is closely  
38 followed by a condition-related factor (asymptomatic nature of the disease) then patient-related  
39 factors (forgetfulness and other causes). With this information, clinicians can implement relevant  
40 measures and allocate resources appropriately to minimise non-adherence.

41

42 **Keywords:** non-adherence, fault tree analysis, Monte Carlo simulation, COVID-19

## 43 **Introduction**

44 A great proportion of patients (especially those with chronic diseases) are non-adherent to their  
45 medication regimen [1,2]. This has led many researchers to the conclusion that non-adherence poses a  
46 significant challenge in medical practice [3,4]. Some authors [5] class non-adherence as an  
47 “epidemic”, while the World Health Organisation (WHO) [1] considers it as “a worldwide problem  
48 with striking magnitude”. Patients’ non-adherence to treatment interventions could have grave  
49 consequences; it could blur the efficacy of treatments [6], create large financial costs to sponsors [7],  
50 cause adverse events or even lead to death in some cases [8].

51 Non-adherence to medications is not limited to any particular disease – acute or chronic; it affects all  
52 diseases [9] and can be influenced by the timing, consistency and persistence of taking medications.  
53 Barriers to medication adherence can vary significantly, ranging from patient-related barriers to  
54 treatment-related barriers. Care providers, the healthcare system and medical staff also contribute to  
55 non-adherence [4,10]. Given this variation in barriers to adherence, there is no single intervention that  
56 will effectively minimise medication non-adherence [4,11]. For example, behavioural modification is  
57 one way to improve adherence however, this is a very challenging solution to implement as human  
58 behaviour is not easily altered. Behavioural modification can take the forms of education, motivation,  
59 support and monitoring [12]. Tackling individual aspects of non-adherence can be done, however,  
60 there is a need for a multidisciplinary approach to medication non-adherence [12].

61 There are various techniques for assessing non-adherence. Though some are classic, such as pill  
62 counting, others employ more sophisticated approaches [13]. Methods for measuring medication  
63 adherence can be generally put in two main categories: direct and indirect [3]. The former provides  
64 proof that patients have taken their medication as prescribed while the latter cannot provide such  
65 proof. Direct methods include body fluid sampling, direct observation of patient and measurement of  
66 biological markers [6]. Indirect methods, which are more widely implemented, include pill count,  
67 patient questionnaire [14], self-report forms, and electronic monitoring devices. Medication adherence  
68 is characterised by three main components: initiation (the point when the patient takes the first dose as

69 prescribed), implementation (period of dosing regimen complying with prescription) and  
70 discontinuation (the point when the patient stops taking medication as prescribed) [15].

71 Measuring medication adherence can be challenging due to the use of adherence measures that have  
72 poor accuracy and reliability [16]. Most of the methods for measuring adherence are performed during  
73 the implementation phase of adherence [3]. Sometimes adherence measurements are performed  
74 during the discontinuation phase [17]. There is limited literature on the methods for measuring  
75 adherence before the initiation phase. Self-report methods of measuring adherence are usually  
76 performed during the implementation phase. However, these self-reporting tools can be used as  
77 historical data to measure adherence before the initiation phase of other future treatments. The  
78 Medication Adherence Reasons Scale (MAR-Scale) and the Morisky Medication Adherence Scale  
79 (MMAS) can be used to measure adherence before the initiation stage [18,19]. Knowing the common  
80 reasons for a patient's non-adherence to medications that they take for their chronic medical  
81 conditions can help clinicians or pharmacists design interventions that will increase the chances of the  
82 patient adhering to the new medication before the patient starting the medication. The MMAS scale  
83 requires the patient to have other chronic medical conditions for which they are taking medications.  
84 The MAR-Scale is unable to fully capture and analyse system conditions that may contribute to non-  
85 adherence but may not be directly associated with the patient or the medication.

86 Various techniques proposed for improving adherence are complex and ineffective, therefore, they are  
87 unable to realise the full benefits a treatment could deliver [16]. It is rational to assess and measure  
88 patients' likely non-adherence before the initiation stage of medication treatment to improve  
89 adherence. The authors employ a proven probabilistic risk assessment technique to estimate the  
90 likelihood of non-adherence before the initiation stage. The results of this study help clinicians to  
91 identify and assess barriers to adherence; this aids them in the development of non-adherence  
92 mitigating strategies and allocation of resources to improve adherence before the initiation stage of  
93 medication adherence.

## 94 **Method**

### 95 **Fault Tree Analysis (FTA)**

96 Fault Tree Analysis (FTA) [20], since its inception, has been used mostly in the engineering sector. It  
97 is a tree-like graphical representation of how basic components failures (basic events) of a system can  
98 propagate to cause a total system failure (top-event). Events are logically connected using the Boolean  
99 gates AND, OR and sometimes the Priority-AND (PAND) gates – depicted in Fig 1. The AND gate  
100 (conjunction) represents the situation where all children events of an output event need to occur for  
101 the output event to occur. The OR (disjunction) gate represents the situation where at least one child  
102 event of an output event need to occur to trigger the occurrence of the output event. The Priority-AND  
103 (PAND) gate represents the scenario where all the children events of an output event occur in a strict  
104 sequence – one after another – for the output event to occur.

#### 105 **Fig 1. FTA Logic Gates**

106 In Fig 1X, the output event  $Q$  is triggered when its input (or child) events  $A$  and  $B$  have occurred  
107 within a given time,  $t$ . In Fig 1Y, the output event  $Q$  is triggered after a given time,  $t$ , when at least  
108 one of its input events –  $A$  or  $B$  – have occurred. Fig 1Z depicts the PAND gate where the output  
109 event  $Q$  is triggered after a given time  $t$  only when its input events  $A$  occurs before  $B$ . For a detailed  
110 description of how FTA is performed, the reader is referred to Vesely et al. [20]. In a logical  
111 expression, the AND, OR and PAND gates are represented by the symbols,  $*$ ,  $+$  and  $<$  respectively.

112 Once a system has been translated into a fault tree, it can be analysed logically (qualitatively). The  
113 logical analysis involves the determination of minimal cut sets (MCS) using Boolean algebra. MCS is  
114 the smallest combination of basic events that are *necessary* and *sufficient* to cause the top event.

115 *Necessary* means each basic event in the MCS is needed for the top event to occur and *sufficient*  
116 means the MCS does not need the occurrence of additional events to cause the top event occurrence.

117 In addition to creating MCS, the logical analysis also reveals single points of failure of a system and  
118 reveals relationships between components. Quantitative analysis or probabilistic analysis involves the

119 evaluation of the probability of the system failing using the MCSs. The probability,  $P$ , of the PAND,  
120 AND and OR (in order of precedence), within a given time  $t$ , for an events  $X_1 \dots X_n$  can be calculated  
121 using Equations (1), (2) and (3) respectively [20]. Equation (1) is limited to exponentially distributed  
122 independent events.

$$P\{X_n < X_{n-1} < \dots < X_2 < X_1\}(t) = \prod_{i=1}^n \lambda_i \sum_{k=0}^n \left[ \frac{e^{(a_k t)}}{\prod_{\substack{j=0 \\ j \neq k}}^n (a_k - a_j)} \right] \quad (1)$$

123  
124 Where  $a_0 = 0$  and  $a_m = -\sum_{j=1}^m \lambda_j$  for  $m > 0$ .

$$P\{X_1 * X_2 * \dots * X_{n-1} * X_n\}(t) = \prod_{i=1}^n P\{X_i\}(t) \quad (2)$$

125

$$P\{X_1 + X_2 + \dots + X_{n-1} + X_n\}(t) = 1 - \left\{ \prod_{i=1}^n (1 - P\{X_i\}(t)) \right\} \quad (3)$$

126

127 To improve the overall reliability of the system, one could perform criticality/sensitivity analysis [20]  
128 to determine how individual components contribute to the system failure. The results of a sensitivity  
129 analysis enable investigators to implement mitigating strategies, know the quality of components to  
130 use and allocate resources appropriately to improve the overall reliability of the system.

## 131 **GoldSim Software**

132 Most traditional FTA-based techniques have some limitations; they are mostly limited to analytical  
133 approaches with exponentially distributed component failures, they cannot capture repairable events  
134 and they are unable to process other system environment data, such as the time of operation. To  
135 evaluate real-world scenarios, one needs to overcome such limitations because real-world events are  
136 dynamic, mostly repairable, and could have different failure distributions. These limitations are  
137 addressed by GoldSim software [21]. GoldSim is a software capable of performing the modelling and  
138 probabilistic analysis of complex real-world systems using Monte Carlo simulation. It has features for  
139 representing the classical Boolean gates AND and OR. The PAND gate can be modelled accurately  
140 using dynamic and intuitive elements in GoldSim.

## 141 **Non-Adherence Tree Analysis (NATA)**

142 The authors propose the Non-Adherence Tree Analysis (NATA) – a systematic and holistic technique  
143 heavily based on the fault tree analysis technique. Unlike FTA where the primary focus of the  
144 investigation is the reliability of a system using failure data (such as failure rate), the primary focus on  
145 the investigation in NATA is non-adherence (or discontinuation of medication) using factors that  
146 trigger non-adherence. NATA follows the guidelines of the classical FTA, however, new terms are  
147 defined in this study to reflect its novel domain of application; these terms have been adapted from  
148 classical FTA definitions [20]. Examples will be based on this scenario: *in a study, 20 patients (out of*  
149 *100 patients) fail to take their medication as prescribed during a 10-day medication regimen. Out of*  
150 *the 20 non-adherent patients, 6 were non-adherent due to forgetfulness (FORG), 4 due to side effects*  
151 *(SIDE) and 10 due to other factors (OTHER).*

152 **Days of Medication Adherence (DoM):** This is the total number of days a medication  
153 should be taken in a treatment regimen for a given study.

154 **Number of participants (NoP):** This is the total number of participants in a study.

155 **Non-Adherence (NA):** This is known as the top event in classical FTA. NA represents the  
156 situation where a prescription to a medication regimen has not been followed as instructed.  
157 Meaning, NA is discontinuation in adherence to the medication before the end of prescribing  
158 period [15].

159 **Non-adherence tree (NAT):** A graphical top-down deductive structure that represents the  
160 non-adherence factors as nodes with Boolean logic gates connecting these nodes to show the  
161 relationship between them. Fig 2 is a simple NAT for the scenario. When creating NATs,  
162 additional information such as the time of operation, replacements, repair/resolution, etc., can  
163 be included in the rectangle of the corresponding non-adherence factor.

164 **Fig 2. A Non-Adherence Tree (NAT)**

165 **Non-Adherence Factor (NAF):** This is synonymous to an event in FTA. It is a binary  
166 outcome indicating if a factor leading to medication discontinuation has occurred or not. It is  
167 true when the factor has occurred and false otherwise. This could be *FORG*, *SIDE* or *OTHER*.

168 **Basic NAF:** This is synonymous to a basic event in FTA. It is a discrete NAF that cannot be  
169 decomposed into other NAF. This is *FORG* and *SIDE*; *OTHER* could be broken into other  
170 NAFs if need be.

171 **Non-Adherence Count (NAC):** This is the cumulative number of patients who are non-  
172 adherent in a study, clinical trial or medication administration process. This is calculated as  
173 the sum of the count of all the occurrences of NAFs. This can be expressed as:

$$NAC = \sum_{i=1}^n Count(NAF_i)$$

174 From the scenario,

$$NAC = Count(FORG) + Count(SIDE) + Count(OTHER) = 6 + 4 + 10 = 20$$

175 NAC could also be expressed in terms of the number of days elapsed using NACX, where X is  
176 the number of days. For example, NAC3 = 8, means 8 participants were non-adherent by Day  
177 3 (counting from Day 1) of a medication regimen.

178 **GrandNoP:** this represents the total number of non-adherent patients from *n* different studies  
179 and it can be evaluated as:

$$GrandNoP = \sum_{i=1}^n NoP_i$$

180 **Non-Adherent Rate per Study (NARS):** This is the number of occurrences of a particular  
181 NAF per the NoP and can be defined as:

$$NARS = \frac{NAF}{NoP}$$

182 Therefore, the NARS for *FORG* can be evaluated as

$$NARS_{FORG} = \frac{6}{100} = 0.06$$

183 **Non-Adherent Rate (NAR):** This is synonymous to failure rate or hazard function in FTA.

184 NAR is the rate of occurrences (NAR) per the duration of the medication regimen – usually

185 expressed in days. NAR can be expressed as,

$$NAR = \frac{NARS}{DoM}$$

186 Therefore, the NAR for *FORG* can be evaluated as

$$NAR_{FORG} = \frac{0.06}{10} = 0.006$$

187 **Weighted NAR (WNAR):** where NARs are to be sourced from multiple studies, it is useful

188 to have a weighted NAR. The WNAR for a particular NAF from *n* studies can be evaluated

189 as:

$$WNAR_{NAF} = \sum_{i=1}^n \frac{NAR_{NAF(i)} * NoP_i}{GrandNoP}$$

190 **Non-Adherence Factor Probability:** This is the probability that a particular NAF will occur

191 and it is represented by P(NAF). The determination of the P(NAF) is based on the probability

192 distribution of the NAF. For example, given a duration (*d*) of 1 and 10 days respectively, if

193 *FORG* is exponentially distributed, P(*FORG*) can be evaluated as:

$$P(FORG_{NAC1}) = 1 - e^{-(NAR*d)} = 1 - e^{-(0.006*1)} = 0.005982$$

$$P(FORG_{NAC10}) = 1 - e^{-(NAR*d)} = 1 - e^{-(0.006*10)} = 0.058235$$

194 **Non-Adherence Probability:** This is the overall non-adherence probability – the probability

195 that there will be discontinuation as a result of NAFs at the end of a medication regimen.

196 Represented by P(NA), the non-adherence probability can be evaluated from Eqn 3.

197 Therefore, from the scenario, given a duration (*d*) of 10 days, P(NA) is

$$P(NA) = 1 - (1 - P(FORG)) * (1 - P(SIDE)) * (1 - P(OTHER)) = 0.18127$$

## 198 Results

199 To demonstrate the usefulness of NATA, it is applied to a COVID-19 treatment intervention clinical  
200 trial. Several clinical trials of drugs targeting COVID-19 have been registered in China [22].  
201 Remdesivir, a nucleotide analogue, and chloroquine, an anti-malarial compound, have both shown  
202 inhibition of the new coronavirus [23]. As of April 2020, several clinical trials are testing the  
203 therapeutic efficacy of remdesivir and hydroxychloroquine (ClinicalTrials.gov: NCT04280705,  
204 NCT04329923) for COVID-19 treatment. If any of these drugs are shown to be safe and efficacious,  
205 they could become the first drug approved for the treatment of COVID-19. In a hospitalized setting,  
206 “there is less consideration given to adherence” [24] therefore, this study will only consider the out-  
207 patient settings. It is assumed that the treatment for out-patients, who usually have mild symptoms, is  
208 a tablet that will be administered for 10 days by the patients themselves - one pill per day - for a study  
209 population of 1000 patients. The diagram in Fig 3 is a NAT for a hypothetical treatment intervention  
210 for COVID-19 using the WHO’s dimensions [1,5] and NAFs from six studies [25–30].

### 211 Fig 3. A NAT for COVID-19 Intervention.

212 In Fig 3, non-adherence has been classified into the 5 WHO dimensions: Social/Economic-related  
213 factors (*SocRel*), Patient-related factors (*PatRel*), Condition-related factors (*ConRel*), Healthcare-  
214 related factors (*HeaRel*) and Therapy-related factors (*TheRel*). These top-level NAFs have sub-NAFs  
215 that are based on factors for non-adherence of oseltamivir, an oral antiviral medication that inhibits  
216 influenza viral replication. This antiviral medication is chosen because of the similarities in symptoms  
217 between influenza infection and COVID-19. Six studies (covering different demographics and  
218 geographic locations) have been used in the determination of these sub-NAFs; they are henceforth  
219 referred to as *Study 1* [25], *Study 2* [26], *Study 3* [27], *Study 4* [28], *Study 5* [29] and *Study 6* [30].

220 In general, there is a strong correlation between family/social support networks for patients and their  
221 adherence to a medication regimen [31]. Patients with COVID-19 require self-isolation to avoid the  
222 spread of the disease. Therefore, limited social support (*SocSup*) and limited healthcare access  
223 (*HeaAcc*) have been considered as NAFs contributing to *SocRel*. Since this intervention is novel, it is

224 assumed that a NAF in the *HeaRel* category is “lack of prior knowledge of adherence” (*PriKno*) [1,5]  
225 in addition to limited tablets (*NoTab*) and clinical improvement (*ClinImp*). The medicine delivery  
226 system in the hospital can also contribute to *HeaRel* if both the ICT (*IctSys*) and manual (*ManSys*)  
227 delivery systems fail. NAFs contributing to *PatRel* include patients’ forgetfulness (*Forgot*), choice of  
228 not taking the medication (*NoMed*) and other patient-related factors (*Other*). *ConRel* and *TheRel* have  
229 only one NAF each – no symptoms (*NoSym*) and side effects (*SidEff*) respectively.

## 230 **Logical Analysis**

231 Using basic Boolean logic, the MCS for non-adherence can be evaluated as:

$$\begin{aligned} 232 \text{ Non-Adherence} &= \text{SocRel} + \text{PatRel} + \text{ConRel} + \text{HeaRel} + \text{TheRel} \\ 233 &= (\text{SocSup} + \text{HeaAcc}) + (\text{NoMed} + \text{Forgot} + \text{Other}) + \text{NoSys} + (\text{ClinImp} + \text{NoTab} + \\ 234 &(\text{IctSys} * \text{ManSys}) + \text{PriKno}) + \text{SidEff} \\ 235 &= \text{SocSup} + \text{HeaAcc} + \text{NoMed} + \text{Forgot} + \text{Other} + \text{NoSys} + \text{ClinImp} + \text{NoTab} + \\ 236 &\text{PriKno} + \text{SidEff} + (\text{IctSys} * \text{ManSys}) \end{aligned}$$

237 The MCS reveals that there are ten single points of failure in the system. Both *IctSys* and *ManSys*  
238 need to occur together to trigger discontinuation therefore they are not considered single points of  
239 failure. With a quick scan at these single points of failure, investigators can determine which aspect of  
240 the system need backups. For example, *NoTab* is a factor that could be easily and quickly improved to  
241 enhance adherence; not all the other factors can be quickly improved. For a detailed analysis on which  
242 factor contributes most to non-adherence, probabilistic analysis is required. Probabilistic analysis can  
243 only occur when NARs have been determined.

## 244 **Non-Adherence Rates (NARs)**

245 It is assumed that the recruited ambulatory participants would fail to adhere to their medication due to  
246 *HeaAcc* resulting in a WNAR of 1.2E-4/day. It is also assumed that *PriKno* [1,5], has an initial  
247 WNAR of 1.5E-4. This rate reduces by 8 per cent of the initial WNAR multiplied by the number of  
248 elapsed day to represent the increasing knowledge of adherence by the medical team. The *IctSys* and

249 *ManSys* sub-systems responsible for ordering and dispensing the medicine fail at daily rates of  $8.12E-$   
 250  $5$  and  $5.34E-5$  with mean-delay-time-until-repair of 4 hours and 2 hours respectively. There is a 2-day  
 251 delay time until the medication is delivered in case of *NoTab*. From results presented in Belmaker et  
 252 al. [25], it is estimated that the WNAR (per day) for *SocSup* for patients taking oseltamivir who are  
 253 under age 25, between ages 25 and 45 inclusive and over age 45 are  $4.138E-4$ ,  $1.379E-4$ , and  $2.069E-$   
 254  $4$  respectively. Table 1 is a summary of NAFs, NARSs, NARs and WNARs from the six studies [25–  
 255 30].

256 **Table 1. NAFs, NARSs, NARs and WNARs from six studies**

Study (S)	NoTabs	SidEff	NoMed	ClinImp	Forgot	NoSym	Other
<b>S1 (NoP=201, DoM=10)</b>	5	3	4	-	-	-	13
NARS	2.488E-02	1.493E-02	1.990E-02	-	-	-	6.468E-02
NAR (per day)	2.488E-03	1.493E-03	1.990E-03	-	-	-	6.468E-03
<b>S2 (NoP=33, DoM=5)</b>	-	1	-	1	-	-	4
NARS	-	3.030E-02	-	3.030E-02	-	-	1.212E-01
NAR (per day)	-	6.061E-03	-	6.061E-03	-	-	2.424E-02
<b>S3 (NoP=331, DoM=6)</b>	-	9	-	-	21	-	7
NARS	-	2.719E-02	-	-	6.344E-02	-	2.115E-02
NAR (per day)	-	4.532E-03	-	-	1.057E-02	-	3.525E-03
<b>S4 (NoP=313, DoM=7)</b>	-	20	-	-	-	42	16
NARS	-	6.390E-02	-	-	-	1.342E-01	5.112E-02
NAR (per day)	-	9.128E-03	-	-	-	1.917E-02	7.303E-03
<b>S5 (NoP=326, DoM=5)</b>	-	24	-	-	7	13	4
NARS	-	7.362E-02	-	-	2.147E-02	3.988E-02	1.227E-02
NAR (per day)	-	1.472E-02	-	-	4.294E-03	7.975E-03	2.454E-03
<b>S6 (NoP=246, DoM=10)</b>	-	24	1	-	22	-	9
NARS	-	9.756E-02	4.065E-03	-	8.943E-02	-	3.659E-02
NAR (per day)	-	9.756E-03	4.065E-04	-	8.943E-03	-	3.659E-03
<b>WNAR</b>	3.448E-04	8.315E-03	3.448E-04	1.379E-04	4.897E-03	5.931E-03	5.002E-03

257

## 258 Probabilistic Analysis

259 A GoldSim model was created from the NAT in Fig 3 using the data in Table 1. The system was  
 260 simulated over 10 days with a time-step of one hour. For each time-step, 1000 iterations were  
 261 performed to simulate the behaviour of each participant. Fig 4 is a graph depicting the mean P(NA)

262 and the NAC over ten days. P(NA) on Day 0 is zero, however, as the days progress towards Day 10, it  
263 approaches 1; on Day 10, it reaches 0.22 with a 5% and 95% confidence bounds of 0.2 and 0.25  
264 respectively and a standard deviation of 0.42. Missing at least one pill (of the 10 pills) results in non-  
265 adherence. The results predict that 776 participants would take all their medications (10 pills) as  
266 prescribed in ten days; 224 participants would miss at least one pill. This result aligns with the results  
267 of the six studies: adherence to such treatment is very high. The NAF contributing the most to P(NA)  
268 is the *PatRel*. Meaning, patient-related factors are strongly correlated to non-adherence.

#### 269 **Fig 4. Probability of Non-Adherence and Non-Adherent Participants**

270 Cumulatively over the 10 days, the average number of patients who would be non-adherent increases  
271 steadily. By the end of Day 1, it is estimated that 21 would miss their pills. From Day 1 to the end of  
272 Day 5, it is estimated that 105 participants would miss at least one pill. At the end of the medication  
273 regimen, it is estimated that 224 patients would miss at least one of their pills. However, the number  
274 of new daily cases on non-adherence had no clear pattern; there were no new cases on some days  
275 while only 2 new cases of non-adherence would be observed on Day 10. The average NAC to NoP  
276 ratio in the six studies is 0.17; the NAC to NoP ratio for the COVID-19 case study is 0.22. The  
277 difference in ratios is due to the additional NAFs (such as *SocSup*, *HeaAcc* and *PriKno*) added to give  
278 a more accurate dynamic of the behaviour of non-adherence to the COVID-19 disease.

## 279 **Discussion**

280 Based on the NATA results for the case study, a COVID-19 treatment is likely to have the non-  
281 adherence probability predicted in Fig 4. Given the high rate of contagiousness, significant financial  
282 and economic burden, and the number of deaths COVID-19 has caused, there is a need for the result  
283 to improve – that is, increase overall adherence rate. At a glance, it seems that patient-related factors  
284 contribute the most to non-adherence. However, patient-related factors are not solely responsible for  
285 non-adherence; other factors also contribute to non-adherence – this affirms results in previous studies  
286 [1]. Further investigation of the results gives us a different picture. In Fig 5, it can be seen that patient-  
287 related factors contribute about 40% to the non-adherence probability. However, when the constituent

288 NAFs are considered, *SidEff* is the biggest contributor, closely followed by *Forgot*, *NoSym*, *Other*,  
289 etc. This means that clinicians hoping to improve the patients' adherence to a COVID-19 treatment  
290 should concentrate on reducing these factors – more importantly, the *SidEff*. *NoSym* is known to have  
291 a relatively high ratio in known COVID-19 cases [32].

### 292 **Fig 5. Contribution of NAFs to NA**

293 This study has established that NATA can reveal the non-adherence factors clinicians need to know to  
294 allocate resources targeting those non-adherence factors. It is assumed that, given the information  
295 produced by NATA, clinicians decide to reduce *Forgot*, *Other*, *NoSym* and *SidEff* by 20% each  
296 through measures such as using a pillbox, software app, information/education [33], trust in physician  
297 [34] and psychological ownership [35]. The GoldSim model was updated and re-run to determine the  
298 impact of the changes on non-adherence; the results are displayed in Fig 6. As expected, the overall  
299 non-adherence of the improved system has reduced by nearly 4% at a mean of 0.187, 5% and 95%  
300 confident intervals of 0.17 and 0.21 respectively and a standard deviation of 0.39. This reduced the  
301 mean number of tablets wasted from 224 to 187 – saving 37 pills that could potentially increase the  
302 evaluation of the efficacy of the treatment by 0.37%.

### 303 **Fig 6. Improvement of Contribution of NAFs to NA**

304 The significant changes made to the improved model using very generous reduction rates of 20% have  
305 enhanced adherence by 3.7% – not as much as one would have expected. The reason for this big  
306 change but relatively little impact is that all NAFs would have to be reduced to make significant  
307 changes to the overall non-adherence. The results of this case study affirm that no single factor can  
308 fully minimise non-adherence [4,11] and provides empirical proof. However, it is still clear that the  
309 four main contributing NAFs are *SidEff*, *Forgot*, *NoSym* and *Other*; these are factors clinicians should  
310 seek to improve to minimise non-adherence.

## 311 **Contribution of NATA**

312 Adherence measuring techniques are usually implemented when a treatment has already begun. This  
313 study has introduced NATA for predicting patients' adherence behaviour so that measures can be put

314 in place to improve adherence. NATA is not only a pre-treatment technique; it can also be used during  
315 treatment. A NATA model in GoldSim can be updated with changes and re-run to determine how the  
316 changes affect the system. This study has proven that NATA can identify non-adherence factors of a  
317 treatment regimen and their relationships and contribution to overall non-adherence. With such  
318 information, clinicians can implement mitigating strategies to minimise the risk of high non-  
319 adherence. Most of the data used in this study – extracted from other studies – are occurrence rates,  
320 hence it was assumed they were exponentially distributed. However, the proposed solution, NATA  
321 and GoldSim, are not restricted to exponentially distributed rates. Using Monte Carlo simulation, the  
322 proposed solution can model and analyse any case study.

## 323 **Limitation**

324 This study is not without limitations. The data used in the COVID-19 case study are based on a  
325 similar drug – oseltamivir – of a similar disease. The authors assume that the behaviour of COVID-19  
326 patients would be similar to that of the patients who took oseltamivir from six studies. The six studies  
327 from which the data was extracted were diverse in terms of demographics and population; therefore,  
328 for a geographically specific application, the data may need to be streamlined. The simulation for the  
329 case study was modelled to run for ten consecutive days, which is not an accurate reflection of real-  
330 world studies where participants of a trial start on different days. NATA is not a stand-alone solution  
331 for addressing all the issues with non-adherence; it depends on the results of studies and techniques  
332 such as the Medication Adherence Reasons Scale or the Morisky Medication Adherence Scale  
333 (MMAS) for data to perform its analysis. In the future, data for NAFs can be sourced from Big Data  
334 and/or Artificial Intelligence-enabled systems where possible.

## 335 **Conclusion**

336 Non-adherence to a medication regimen is widespread. In addition to financial losses, non-adherence  
337 can blur the efficacy of drugs and lead to loss of lives. Most adherence measuring techniques are  
338 implemented after the patient has started the medication regimen. This article has explored the use of  
339 Fault Tree Analysis (FTA) – an engineering technique for probabilistic risk analysis – to predict the

340 nature of non-adherence. It proposes the Non-Adherence Tree Analysis (NATA) based on classical  
341 FTA for modelling and analysing a medication regimen. Based on the results NATA produces, health  
342 professionals and clinicians can implement strategies and allocate resources to help improve  
343 adherence. NATA can serve as a framework for analysing non-adherence factors in clinical trials and  
344 other drug administration processes. The authors have applied NATA to a hypothetical COVID-19  
345 treatment; the results reveal the factors clinicians should concentrate on to minimise non-adherence.

## 346 **Acknowledgements**

347 The authors would like to thank Prof. Peter Naude for reviewing the article and providing constructive  
348 comments that have contributed immensely to its quality.

## 349 **References**

- 350 [1] De Geest S, Sabaté E. Adherence to long-term therapies: Evidence for action. *Eur J*  
351 *Cardiovasc Nurs* 2003;2:323. [https://doi.org/10.1016/S1474-5151\(03\)00091-4](https://doi.org/10.1016/S1474-5151(03)00091-4).
- 352 [2] Wiecek E, Tonin FS, Torres-Robles A, Benrimoj SI, Fernandez-Llimos F, Garcia-Cardenas V.  
353 Temporal effectiveness of interventions to improve medication adherence: A network meta-  
354 analysis. *PLoS One* 2019;14:e0213432. <https://doi.org/10.1371/journal.pone.0213432>.
- 355 [3] Osterberg L, Blaschke T. Adherence to medication. *N Engl J Med* 2005;353:487–97.
- 356 [4] Shubber Z, Mills EJ, Nacheга JB, Vreeman R, Freitas M, Bock P, et al. Patient-Reported  
357 Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis.  
358 *PLOS Med* 2016;13:e1002183. <https://doi.org/10.1371/journal.pmed.1002183>.
- 359 [5] ASA, ASCP. Medication Adherence – Where Are We Today? Overview 2006.  
360 [http://www.adultmedication.com/overviewofmedicationadherence\\_4.html](http://www.adultmedication.com/overviewofmedicationadherence_4.html) (accessed August  
361 12, 2016).
- 362 [6] Vernon A, Fielding K, Savic R, Dodd L, Nahid P. The importance of adherence in tuberculosis  
363 treatment clinical trials and its relevance in explanatory and pragmatic trials. *PLoS Med*

- 364 2019;16. <https://doi.org/10.1371/journal.pmed.1002884>.
- 365 [7] Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic  
366 impact of medication non-adherence by disease groups: A systematic review. *BMJ Open*  
367 2018;8:16982. <https://doi.org/10.1136/bmjopen-2017-016982>.
- 368 [8] Wu J-R, Moser DK. Medication Adherence Mediates the Relationship Between Heart Failure  
369 Symptoms and Cardiac Event-Free Survival in Patients With Heart Failure. *J Cardiovasc Nurs*  
370 2018;33:40–6. <https://doi.org/10.1097/JCN.0000000000000427>.
- 371 [9] Costa E, Giardini A, Savin M, Menditto E, Lehane E, Laosa O, et al. Interventional tools to  
372 improve medication adherence: Review of literature. *Patient Prefer Adherence* 2015;9:1303–  
373 14. <https://doi.org/10.2147/PPA.S87551>.
- 374 [10] Brown MT, Bussell JK. Medication adherence: WHO cares? *Mayo Clin Proc* 2011;86:304–14.  
375 <https://doi.org/10.4065/mcp.2010.0575>.
- 376 [11] Martin LR, Williams SL, Haskard KB, Dimatteo MR. The challenge of patient adherence.  
377 *Ther Clin Risk Manag* 2005;1:189–99. <https://doi.org/10.1089/bar.2012.9960>.
- 378 [12] Kleinsinger F. The Unmet Challenge of Medication Nonadherence. *Perm J* 2018;22:18–033.  
379 <https://doi.org/10.7812/TPP/18-033>.
- 380 [13] Aldeer M, Javanmard M, Martin RP. A Review of Medication Adherence Monitoring. *Appl*  
381 *Syst Innov* 2018;1:1–27. <https://doi.org/10.3390/asi1020014>.
- 382 [14] Moon SJ, Lee WY, Hwang JS, Hong YP, Morisky DE. Accuracy of a screening tool for  
383 medication adherence: A systematic review and meta-analysis of the Morisky Medication  
384 Adherence Scale-8. *PLoS One* 2017;12. <https://doi.org/10.1371/journal.pone.0187139>.
- 385 [15] Vrijens B, Geest S De, Hughes DA, Przemyslaw K, Demonceau J, Ruppard T, et al. A new  
386 taxonomy for describing and defining adherence to medications. *Br J Clin Pharmacol*  
387 2012;73:691–705. <https://doi.org/10.1111/j.1365-2125.2012.04167.x>.

- 388 [16] Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al.  
389 Interventions for enhancing medication adherence. 2014.  
390 <https://doi.org/10.1002/14651858.CD000011.pub4>.
- 391 [17] Torres-Robles A, Wiecek E, Cutler R, Drake B, Benrimoj SI, Fernandez-Llimos F, et al. Using  
392 dispensing data to evaluate adherence implementation rates in community pharmacy. *Front*  
393 *Pharmacol* 2019;10:1–9. <https://doi.org/10.3389/fphar.2019.00130>.
- 394 [18] Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication  
395 adherence measure in an outpatient setting. *J Clin Hypertens* 2008;10:348–54.  
396 <https://doi.org/10.1111/j.1751-7176.2008.07572.x>.
- 397 [19] Unni EJ, Sternbach N, Goren A. Using the Medication Adherence Reasons Scale (MAR-  
398 Scale) to identify the reasons for non-adherence across multiple disease conditions. *Patient*  
399 *Prefer Adherence* 2019;13:993–1004. <https://doi.org/10.2147/PPA.S205359>.
- 400 [20] Vesely WE, Stamatelatos M, Dugan JB, Fragola J, Minarick J, Railsback J. *Fault Tree*  
401 *Handbook with Aerospace Applications*. Washington DC: NASA Office of Safety and Mission  
402 Assurance; 2002.
- 403 [21] Goldsim. Goldsim. A Dyn Simul Approach to Reliab Model Risk Assess Using GoldSim  
404 2020. [https://www.goldsim.com/downloads/documents/GoldSim\\_Reliability\\_and\\_PRA.pdf](https://www.goldsim.com/downloads/documents/GoldSim_Reliability_and_PRA.pdf)  
405 (accessed December 15, 2018).
- 406 [22] Brüßow H. The Novel Coronavirus – A Snapshot of Current Knowledge. *Microb Biotechnol*  
407 2020;1751-7915.13557. <https://doi.org/10.1111/1751-7915.13557>.
- 408 [23] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively  
409 inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res* 2020;30:269–  
410 71. <https://doi.org/10.1038/s41422-020-0282-0>.
- 411 [24] Kim J, Combs K, Downs J, Tillman F. Medication adherence: The elephant in the room. *US*  
412 *Pharm* 2018;43:30–4.

- 413 [25] Belmaker I, Lyandres M, Bilenko N, Dukhan L, Mendelson E, Mandelboim M, et al.  
414 Adherence with oseltamivir chemoprophylaxis among workers exposed to poultry during  
415 avian influenza outbreaks in southern Israel. *Int J Infect Dis* 2009;13:261–5.  
416 <https://doi.org/10.1016/j.ijid.2008.06.037>.
- 417 [26] Chishti T, Oakeshott P. Do general practice patients who are prescribed Tamiflu® actually  
418 take it? *Br J Gen Pract* 2010;60:535. <https://doi.org/10.3399/bjgp10X514891>.
- 419 [27] Choo D, Hossain M, Liew P, Chowdhury S, Tan J. Side effects of oseltamivir in end-stage  
420 renal failure patients. *Nephrol Dial Transplant* 2011;26:2339–44.  
421 <https://doi.org/10.1093/ndt/gfq737>.
- 422 [28] McVernon J, Mason K, Petrony S, Nathan P, LaMontagne AD, Bentley R, et al.  
423 Recommendations for and compliance with social restrictions during implementation of school  
424 closures in the early phase of the influenza A (H1N1) 2009 outbreak in Melbourne, Australia.  
425 *BMC Infect Dis* 2011;11:1–7. <https://doi.org/10.1186/1471-2334-11-257>.
- 426 [29] Strong M, Burrows J, Stedman E, Redgrave P. Adverse drug effects following oseltamivir  
427 mass treatment and prophylaxis in a school outbreak of 2009 pandemic influenza a(H1N1) in  
428 June 2009, Sheffield, United Kingdom. *Eurosurveillance* 2010;15:1–6.  
429 <https://doi.org/10.2807/ese.15.19.19565-en>.
- 430 [30] Wallensten A, Oliver I, Lewis D, Harrison S. Compliance and side effects of prophylactic  
431 oseltamivir treatment in a school in South West England. *Eurosurveillance* 2009;14:1–4.  
432 <https://doi.org/10.2807/ese.14.30.19285-en>.
- 433 [31] Gu L, Wu S, Zhao S, Zhou H, Zhang S, Gao M, et al. Association of social support and  
434 medication adherence in Chinese patients with type 2 diabetes mellitus. *Int J Environ Res*  
435 *Public Health* 2017;14:1522. <https://doi.org/10.3390/ijerph14121522>.
- 436 [32] Nishiura H, Kobayashi T, Suzuki A, Jung S-M, Hayashi K, Kinoshita R, et al. Estimation of  
437 the asymptomatic ratio of novel coronavirus infections (COVID-19). *Int J Infect Dis* 2020.

438 <https://doi.org/10.1016/j.ijid.2020.03.020>.


439 [33] Agyepong IA, Ansah E, Gyapong M, Adjei S, Barnish G, Evans D. Strategies to improve  
440 adherence to recommended chloroquine treatment regimes: A quasi-experiment in the context  
441 of integrated primary health care delivery in Ghana. *Soc Sci Med* 2002;55:2215–26.  
442 [https://doi.org/10.1016/S0277-9536\(01\)00366-5](https://doi.org/10.1016/S0277-9536(01)00366-5).

443 [34] Lee YY, Lin JL. The effects of trust in physician on self-efficacy, adherence and diabetes  
444 outcomes. *Soc Sci Med* 2009;68:1060–8. <https://doi.org/10.1016/j.socscimed.2008.12.033>.


445 [35] Mifsud M, Molines M, Cases AS, N’Goala G. It’s MY health care program: Enhancing patient  
446 adherence through psychological ownership. *Soc Sci Med* 2019;232:307–15.  
447 <https://doi.org/10.1016/j.socscimed.2019.05.015>.

448


P(NA) and P(NAFs)




Non-adherent count (NAC)




New daily cases of non-adherence




### Contribution to P(NA) - Dimensions




### Contribution to P(NA) - All NAFs




P(NA) and P(NAFs)




Contribution to P(NA) - Dimensions




Contribution to P(NA) - All NAFs






X: AND Gate



Y: OR Gate



Z: NAND Gate

Discontinuation

G01

Forgetfulness  
(FORG)

B01

Side Effects  
(SIDE)

B02

Other factors  
(OTHER)

B03

